RxDoctor Payments Data

Riyad Basir, MD

Critical Care Medicine · Bronx, NYNPI 1649342114

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,600 of the $1,780 with a category attached, or 89.9%. It is spread thinly across 18 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations.

$1,780in general payments, 2019–2025

Across 62 payments — averaging $28.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$342
  • GSK$247
  • AstraZeneca$220
  • Inari Medical, Inc.$180
  • Intuitive Surgical$129
  • Chiesi USA, Inc.$126
  • plus $537 from 12 others
$70,426in research payments, 2019–2025

Across 17 payments — averaging $4142.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$70K

What the payments were for

  • Food & beverage$1,60090%
  • Education$1207%
  • Gifts$603%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,780 in reported general payments places this provider in the 80th percentile of 442 critical care medicine providers in New York.

See all critical care medicine providers in New York

Medicare billing

Part B allowed, 2024
$15,269
Medicare patients
78
Services billed
187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ventolin HfaAlbuterol Sulfate11$562
Albuterol Sulfate HfaAlbuterol Sulfate14$425

Paid to pharmacies, not to this prescriber.

Other critical care medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →